Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 573

The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Correale, Jorge, Gaitán, María I., Ysrraelit, María C., Fiol, Marcela P.·2016·Brain

Abstract

During the past decades, better understanding of relapsing-remitting multiple sclerosis disease mechanisms have led to the development of several disease-modifying therapies, reducing relapse rates and severity, through immune system modulation or suppression. In contrast, current therapeutic options for progressive multiple sclerosis remain comparatively disappointing and challenging. One possible explanation is a lack of understanding of pathogenic mechanisms driving progressive multiple sclerosis. Furthermore, diagnosis is usually retrospective, based on history of gradual neurological worsening with or without occasional relapses, minor remissions or plateaus. In addition, imaging methods as well as biomarkers are not well established. Magnetic resonance imaging studies in progressive multiple sclerosis show decreased blood-brain barrier permeability, probably reflecting compartmentalization of inflammation behind a relatively intact blood-brain barrier. Interestingly, a spectrum of inflammatory cell types infiltrates the leptomeninges during subpial cortical demyelination. Indeed, recent magnetic resonance imaging studies show leptomeningeal contrast enhancement in subjects with progressive multiple sclerosis, possibly representing an in vivo marker of inflammation associated to subpial demyelination. Treatments for progressive disease depend on underlying mechanisms causing central nervous system damage. Immunity sheltered behind an intact blood-brain barrier, energy failure, and membrane channel dysfunction may be key processes in progressive disease. Interfering with these mechanisms may provide neuroprotection and prevent disability progression, while potentially restoring activity and conduction along damaged axons by repairing myelin. Although most previous clinical trials in progressive multiple sclerosis have yielded disappointing results, important lessons have been learnt, improving the design of novel ones. This review discusses mechanisms involved in progressive multiple sclerosis, correlations between histopathology and magnetic resonance imaging studies, along with possible new therapeutic approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/aww258

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 181 references

Research works printed but not linked: 8

  1. Andersson, 1999, Multiple sclerosisthatis progressive from the time of onset: clinical characteristicsand progression of disability, Ann Neurol, 56, 1138
  2. 10.1136/jnnp.2010.205021 · doi:10.1136/jnnp.2010.205021
  3. Cadavid, 2015, BIIBo33, anti-LINGO treatment of relapsing-remitting Multiple Sclerosis: Basal data of the Phase 2 SYNERGY Trial, Neurology, 84 (14 Suppl), P7204, 10.1212/WNL.84.14_supplement.P7.204 · doi:10.1212/wnl.84.14_supplement.p7.204
  4. Cadavid, 2016, Evidence that the Anti-Lingo-1 monoclonal antibody BIIBo33protects against multifocal visual evoked potential amplitud loss in the fellow eye of subjects with unilateral acute optic neuritis, Neurology, 86 (16 Suppl), I10.009, 10.1212/WNL.86.16_supplement.I10.009 · doi:10.1212/wnl.86.16_supplement.i10.009
  5. 10.1007/s00415-011-6212-9 · doi:10.1007/s00415-011-6212-9
  6. 10.1111/j.1755-5949.2008.00072.x · doi:10.1111/j.1755-5949.2008.00072.x
  7. 10.1191/1352458503ms970oa · doi:10.1191/1352458503ms970oa
  8. Tourbah A Lebrun-Frenay C Edan G Clanet M Papex C Vukusic S . 24-Month-treatment with-MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of the MS-SPI trial extension phase. Neurology 2016; 86: Suppl S49.004 · doi:10.26226/morressier.59a3e8b7d462b8028d895787

Cited by

See all 573

Metadata

Authors
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P.
Venue
Brain
Published
2016-10-29
Volume
140
Issue
3
Pages
aww258
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2544079919
Cited by
573
References
181
FWCI
23.45
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progressive multiple sclerosis: from pathogenic mechanisms to treatment. https://app.cochat.ai/papers/10.1093/brain/aww258
The paper
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016). Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. https://doi.org/10.1093/brain/aww258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.